Antibody and cytokine production in response to SARS-CoV-2: vaccine versus hybrid immunity comparison
Vol. 83 (2024), SCIENTIFIC NOTE
Vol. 83 (2024)

Antibody and cytokine production in response to SARS-CoV-2: vaccine versus hybrid immunity comparison

SCIENTIFIC NOTE
https://doi.org/10.53393/rial.2024.v.83.40020
Published 2024-06-24
Júlia Bombini Faustini
Instituto Lauro de Souza Lima, Bauru, SP, Brasil
https://orcid.org/0000-0002-6472-7431
Ana Paula Campanelli
Departamento de Microbiologia e Imunologia, Faculdade de Odontologia de Bauru, Universidade de São Paulo, Bauru, SP, Brasil
https://orcid.org/0000-0002-0536-5469
Thais Fernanda de Campos Fraga da Silva
Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
https://orcid.org/0000-0002-2053-8938
Vânia Nieto Brito de Souza
Instituto Lauro de Souza Lima, Bauru, SP, Brasil
https://orcid.org/0000-0002-4963-769X
PDF (Português (Brasil))

Keywords

SARS-CoV-2
COVID-19
Vaccines
Immune Response
Antibodies

How to Cite

1.
Bombini Faustini J, Campanelli AP, de Campos Fraga da Silva TF, Nieto Brito de Souza V. Antibody and cytokine production in response to SARS-CoV-2: vaccine versus hybrid immunity comparison. Rev Inst Adolfo Lutz [Internet]. 2024 Jun. 24 [cited 2024 Nov. 21];83:1-6,e40020. Available from: https://periodicos.saude.sp.gov.br/RIAL/article/view/40020
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

The immune response generated by SARS-CoV-2 vaccination protocols and natural infection remains incompletely understood. We compared individuals who received a heterologous vaccination scheme with a booster shot (vaccine immunity) to those who experienced a mild COVID-19 episode (hybrid immunity) during the same timeframe. Our findings revealed similar levels of SARS-CoV-2 antibodies in both groups. Stimulation by viral antigen in mononuclear cell cultures induced pro-inflammatory cytokines in both groups, while individuals with vaccine immunity exhibited lower IL-17. These results suggest that a vaccine booster can induce an immune response in previously vaccinated individuals comparable to that elicited by natural SARS-CoV-2 infection.

https://doi.org/10.53393/rial.2024.v.83.40020
PDF (Português (Brasil))

References

Fiolet H, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clinical Microbiology and Infection. 2022;28(2):202-221. https://doi.org/10.1016/j.cmi.2021.10.005

Vespa S, Simeone P, Catitti G, Buca D, Bellis D, Pierdomenico L et al. SARS-CoV-2 and immunity: natural infection compared with vaccination. Int J Mol Sci. 2022;23:8982. https://doi.org/10.3390/ijms23168982

Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARSCoV-2. Lancet Infect Dis. 2021;21(2):e26-e35. https://doi.org/10.1016/S1473-3099(20)30773-8

Rossi C, Lanuti P, Cicalini I, Bellis D, Pierdomenico L, Boccio P et al. BNT162b2 mRNA vaccination leads to long-term protection from COVID-19 disease. Vaccines. 2021;9:1164. https://doi.org/10.3390/vaccines9101164

Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84. https://doi.org/10.1056/NEJMoa2114583

Olajide OA, Iwuanyanwu VU, Adegbola OD, Al-Hindawi AA. SARS-CoV-2 spike glycoprotein S1 induces neuroinflammation in BV-2 microglia. Mol Neurobiol. 2022;59(1):445-58. https://doi.org/10.1007/s12035-021-02593-6

Wu X, Xia T, Shin WJ, Yu KM, Jung W, Herrmann A et al. Viral mimicry of Interleukin-17A by SARSCoV-2 ORF8. mBio. 2022;13(2):e00402-22. https://doi.org/10.1128/mbio.00402-22

Udomsinprasert W, Jittikoon J, Sangroongruangsri S, Chaikledkaew U. Circulating levels of Interleukin-6 and Interleukin-10, but not tumor necrosis factor-alpha, as potential biomarkers of severity and mortality for COVID-19: systematic review with meta-Analysis. J Clin Immunol. 2020;41:11-22. https://doi.org/10.1007/s10875-020-00899-z

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2024 Júlia Bombini Faustini, Ana Paula Campanelli, Thais Fernanda de Campos Fraga da Silva, Vânia Nieto Brito de Souza

Downloads

Download data is not yet available.